Asset profile
tamoxifen
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tamoxifen: this drug | Approved | Small molecule | Estrogen receptor | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Imlunestrant | Approved | Small molecule | Estrogen receptor | ||
| Vepdegestrant | Approved | Small molecule | Estrogen receptor | ||
| Camizestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Giredestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Palazestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) |
…and 52 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Elacestrant · HR+/HER2- Metastatic Breast Cancervs Fulvestrant · HR+/HER2- Metastatic Breast Cancervs Vepdegestrant · HR+/HER2- Metastatic Breast Cancervs Camizestrant · HR+/HER2- Metastatic Breast Cancervs Giredestrant · HR+/HER2- Metastatic Breast Cancervs Palazestrant · HR+/HER2- Metastatic Breast Cancer
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(37 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
October 2026 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-10-14 · NCT03707340 · CT.gov ↗
What to watch
November 2026 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04906395 · CT.gov ↗
What to watch
December 2026 (3)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT04174352 · CT.gov ↗
What to watch
Phase 2Glioblastoma MultiformeRecruiting
Est. primary completion 2026-12 · NCT04765098 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05780567 · CT.gov ↗
What to watch
2027 (8)
January 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-01 · NCT06195306 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT06364267 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Pancreatic NeoplasmsRecruiting
Est. primary completion 2027-02-28 · NCT06914674 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT05501704 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07499999 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
2028 (9)
February 2028 (1)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02 · NCT04740697 · CT.gov ↗
What to watch
March 2028 (2)
May 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-07 · NCT07806630 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1Pancreatic Cyst, Pancreatic Mucinous Cystic NeoplasmRecruiting
Est. primary completion 2028-11 · NCT06320990 · CT.gov ↗
What to watch
Phase 2Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2028-11-30 · NCT06434064 · CT.gov ↗
What to watch
2029 (2)
2030 (6)
March 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2030-03 · NCT05645536 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
October 2030 (2)
December 2030 (1)
Phase 1CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood, Medulloblastoma, Group 3 …Recruiting
Est. primary completion 2030-12-31 · NCT06942039 · CT.gov ↗
What to watch
2031 (4)
April 2031 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-04-08 · NCT04852887 · CT.gov ↗
What to watch
June 2031 (1)
Phase 3Ductal Carcinoma In Situ, DCISRecruiting
Est. primary completion 2031-06 · NCT07762885 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2032-05-02 · NCT06223698 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch
2036 (1)
August 2036 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2036-08 · NCT07502820 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.